Immunotherapy and precision medicine remain 2 of the most active and challenging areas of investigation in pancreatic ductal adenocarcinoma (PDAC), a malignancy long recognized for its immune-resistant biology and limited responsiveness to…
Emerging Immunotherapy and Precision Medicine Strategies Take Aim at PDAC Treatment Resistance
